Anika Therapeutics, Inc. (ANIK)
NASDAQ: ANIK · Real-Time Price · USD
16.53
-0.58 (-3.39%)
Nov 1, 2024, 4:00 PM EDT - Market closed

Company Description

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.

The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform.

Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief.

The company’s joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions.

In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products.

The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

Anika Therapeutics, Inc.
Anika Therapeutics logo
Country United States
Founded 1983
IPO Date Apr 29, 1993
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 357
CEO Cheryl Blanchard

Contact Details

Address:
32 Wiggins Avenue
Bedford, Massachusetts 01730
United States
Phone 781 457 9000
Website anika.com

Stock Details

Ticker Symbol ANIK
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000898437
CUSIP Number 035255108
ISIN Number US0352551081
Employer ID 04-3145961
SIC Code 3841

Key Executives

Name Position
Dr. Cheryl Renee Blanchard Ph.D. President, Chief Executive Officer and Director
Anne Nunes Senior Vice President and Chief Operating Officer
David Colleran J.D. Executive Vice President, General Counsel and Corporate Secretary
Michael L. Levitz Executive Officer
Stephen D. Griffin Executive Vice President, Chief Financial Officer and Treasurer
Ian W. McLeod Vice President and Chief Accounting Officer
Mark Namaroff Vice President of Investor Relations, ESG and Corporate Communications
James Chase Senior Vice President of International Sales and Marketing
Ben Joseph Vice President of Commercial and Corporate Development
Lisa Funiciello Vice President of Human Resources

Latest SEC Filings

Date Type Title
Oct 31, 2024 8-K Current Report
Oct 31, 2024 8-K Current Report
Oct 23, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Aug 8, 2024 10-Q Quarterly Report
Aug 8, 2024 8-K Current Report
Jul 11, 2024 8-K Current Report
Jun 25, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Jun 11, 2024 ARS Filing
Jun 11, 2024 DEF 14A Other definitive proxy statements
May 31, 2024 S-8 Securities to be offered to employees in employee benefit plans